Rubicon Research
Thane, India· Est.
Indian pharma firm delivering 55+ FDA‑approved generics and specialty formulations through proprietary delivery technologies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Indian pharma firm delivering 55+ FDA‑approved generics and specialty formulations through proprietary delivery technologies.
General MedicineOphthalmologyNeurologyCardiovascular
Technology Platform
Proprietary drug‑delivery technologies (10 patents) enabling enhanced bioavailability, controlled release, and novel administration routes across oral, ophthalmic, and injectable formats.
Opportunities
Expansion of specialty and drug‑device combination products in the US market, leveraging proprietary delivery platforms and cross‑border regulatory expertise.
Risk Factors
Regulatory delays, intense price competition in generics, and the need for sustained R&D funding to advance a large pipeline.
Competitive Landscape
Competes with global generics manufacturers and specialty firms; differentiation stems from its patented delivery technologies and integrated end‑to‑end development capabilities.